The US Foods and Drugs Administration (USFDA) has taken a hard stand against US-based pharmaceutical firm Mylan, regarding the pending approval of selling the generic version of the 7.2 billion dollar drug, Lipitor, to Indian drug maker Ranbaxy Laboratories. In a petition filed in the court of California, the USFDA has requested that Mylan
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
